Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19

The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Jie, Wang, Feng, Huang, Zhiwei, Chen, Xiaobo, Wang, Yuliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052468/
https://www.ncbi.nlm.nih.gov/pubmed/33926774
http://dx.doi.org/10.1016/j.cyto.2021.155544
_version_ 1783679925550579712
author Geng, Jie
Wang, Feng
Huang, Zhiwei
Chen, Xiaobo
Wang, Yuliang
author_facet Geng, Jie
Wang, Feng
Huang, Zhiwei
Chen, Xiaobo
Wang, Yuliang
author_sort Geng, Jie
collection PubMed
description The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of finding effective and low-toxicity drugs to mitigate CRS, IL-1 blockade agents, which are one of the safest ways to stop this overwhelming innate immune response, are already available in several preliminary reports or are under observational trials and may offer an important treatment option in hyperinflammatory COVID-19. In this review, we described the key information in both case reports and clinical studies on the potential beneficial features of IL-1 inhibitors in COVID-19 patients.
format Online
Article
Text
id pubmed-8052468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-80524682021-04-19 Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19 Geng, Jie Wang, Feng Huang, Zhiwei Chen, Xiaobo Wang, Yuliang Cytokine Review Article The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of finding effective and low-toxicity drugs to mitigate CRS, IL-1 blockade agents, which are one of the safest ways to stop this overwhelming innate immune response, are already available in several preliminary reports or are under observational trials and may offer an important treatment option in hyperinflammatory COVID-19. In this review, we described the key information in both case reports and clinical studies on the potential beneficial features of IL-1 inhibitors in COVID-19 patients. Published by Elsevier Ltd. 2021-07 2021-04-17 /pmc/articles/PMC8052468/ /pubmed/33926774 http://dx.doi.org/10.1016/j.cyto.2021.155544 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Geng, Jie
Wang, Feng
Huang, Zhiwei
Chen, Xiaobo
Wang, Yuliang
Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title_full Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title_fullStr Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title_full_unstemmed Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title_short Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
title_sort perspectives on anti-il-1 inhibitors as potential therapeutic interventions for severe covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052468/
https://www.ncbi.nlm.nih.gov/pubmed/33926774
http://dx.doi.org/10.1016/j.cyto.2021.155544
work_keys_str_mv AT gengjie perspectivesonantiil1inhibitorsaspotentialtherapeuticinterventionsforseverecovid19
AT wangfeng perspectivesonantiil1inhibitorsaspotentialtherapeuticinterventionsforseverecovid19
AT huangzhiwei perspectivesonantiil1inhibitorsaspotentialtherapeuticinterventionsforseverecovid19
AT chenxiaobo perspectivesonantiil1inhibitorsaspotentialtherapeuticinterventionsforseverecovid19
AT wangyuliang perspectivesonantiil1inhibitorsaspotentialtherapeuticinterventionsforseverecovid19

Ejemplares similares